Martin Auster - Sep 5, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Financial Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Sep 5, 2023
Transactions value $
-$863,334
Form type
4
Date filed
9/7/2023, 04:31 PM
Previous filing
Jul 26, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale -$591K -18.3K -38.46% $32.26 29.3K Sep 5, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$272K -8.14K -27.77% $33.41 21.2K Sep 5, 2023 Direct F1, F3
transaction VTYX Common Stock Sale -$102 -3 -0.01% $33.98 21.2K Sep 5, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2022.
F2 Represents the weighted average share price of an aggregate total of 18,327 shares sold in the price range of $31.97 to $32.8321. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 8,142 shares sold in the price range of $32.97 to $33.96. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.